News

Fiscal 2009 guidance reaffirmed For the fiscal year ending September 30, 2009, management expects net sales to be in the range of $151 million to $156 million and

Baxter reported fourth quarter net income of $569 million, an increase of 19%from the $478 million reported in the fourth quarter of 2007. Earnings per diluted share of

The UK Medicines and Healthcare Products Regulatory Agency’s approval for the trial has been given subject to provision of data both from an ongoing preclinical study and from

This cost-cutting initiative includes the elimination of more than 900 open positions. The approximately 600 associates affected by the layoff will receive both severance pay and outplacement assistance

The first patient was recently symptomatic and more than 90 years old. The greater than 95% stenosis in the internal carotid artery was successfully stented under protection by

The agreement is said to be a strategic milestone for both companies, strengthening Sunquest’s mission to increase international market share and HCS’s commitment to bring healthcare technology to

The company is seeking approval for Bepreve as an eye drop treatment for ocular itching associated with allergic conjunctivitis. Ista says that Bepreve is a non-sedating, highly selective

MD Anderson is conducting a clinical trial to explore a cord blood expansion technology called ‘Co-culture’. Cord blood is a valuable, non-controversial source of stem cells with effect

This international, multicenter, open-label clinical trial is sponsored by Merck & Co and is part of the Vantage program. The trial will enroll 142 patients from more than